Julia Haas

US Patent:

8119592, Feb 21, 2012

Filed:

Oct 10, 2006

Appl. No.:

12/089895

Inventors:

Leonid Beigelman - San Mateo CA, US
Scott D. Seiwert - Pacifica CA, US
Lawrence Blatt - San Francisco CA, US
Steven Andrews - Longmont CO, US
Julia Haas - Boulder CO, US

Assignee:

InterMune, Inc. - Brisbane CA

International Classification:

A61K 38/12

US Classification:

514 43, 514 211, 530317

Abstract:

Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV.

US Patent:

8450322, May 28, 2013

Filed:

Sep 21, 2009

Appl. No.:

13/063894

Inventors:

Steven D. Andrews - Boulder CO, US
Julia Haas - Boulder CO, US
Yutong Jiang - Boulder CO, US
Gan Zhang - Niwot CO, US

Assignee:

Array BioPharma Inc. - Boulder CO

International Classification:

A01N 43/58
A01N 43/60
A61K 31/495
C07D 487/00

US Classification:

514250, 544236

Abstract:

Compounds of Formula (I): in which R, R, R, R, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.

US Patent:

8513263, Aug 20, 2013

Filed:

Oct 21, 2009

Appl. No.:

13/125263

Inventors:

Julia Haas - Boulder CO, US
Steven W. Andrews - Boulder CO, US
Yutong Jiang - Boulder CO, US
Gan Zhang - Boulder CO, US

Assignee:

Array BioPharma Inc. - Boulder CO

International Classification:

A01N 43/90
A61K 31/519
C07D 487/00

US Classification:

5142593, 544281

Abstract:

Compounds of Formula (I) in which R, R, R, R, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.

US Patent:

20050222146, Oct 6, 2005

Filed:

Dec 15, 2004

Appl. No.:

11/011781

Inventors:

Andrew Fryer - Erie CO, US
Makoto Shiozaki - Osaka, JP
Nicole Littmann - Erie CO, US
Takashi Inaba - Osaka, JP
Steven Andrews - Longmont CO, US
Katsutaka Yasue - Osaka, JP
Ellen Laird - Longmont CO, US
Masahiro Yokota - Osaka, JP
Julia Haas - Boulder CO, US
Hiroto Imai - Osaka, JP
Katsuya Maeda - Osaka, JP
Yuichi Shinozaki - Osaka, JP
Yoshikazu Hori - Osaka, JP

International Classification:

A61K031/5377
A61K031/496
A61K031/381
C07D049/02
C07D413/02

US Classification:

514232200, 514252130, 514445000, 544145000, 549071000, 544379000

Abstract:

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1): wherein Ris —W-A—W-A, W is —(CH)—X—(CH)—, wherein Wis —(CH)—X—(CH)—, m, m1, n and n1 are the same or different and each is 0 to 6, X and Xare the same or different and each is a single bond, etc., Ais an optionally substituted Chydrocarbon ring group, etc. and Ais a substituted Chydrocarbon ring group etc.; Ris —(CH)—CO—R, etc., wherein r is to and Ris a Calkoxy group, etc.; Rand Rare the same or different and each is a hydrogen atom, a Calkyl group, etc.; and Ris —CORetc.; Rand Rare the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

US Patent:

20060199826, Sep 7, 2006

Filed:

Dec 15, 2004

Appl. No.:

11/011773

Inventors:

Takashi Inaba - Osaka, JP
Julia Haas - Boulder CO, US
Makoto Shiozaki - Osaka, JP
Nicole Littmann - Erie CO, US
Katsutaka Yasue - Osaka, JP
Steven Andrews - Longmont CO, US
Atushi Sakai - Osaka, JP
Andrew Fryer - Erie CO, US
Takafumi Matsuo - Osaka, JP
Ellen Laird - Longmont CO, US
Akira Suma - Osaka, JP
Yuichi Shinozaki - Osaka, JP
Yoshikazu Hori - Osaka, JP
Hiroto Imai - Osaka, JP
Tamotsu Negoro - Osaka, JP

International Classification:

A61K 31/496
A61K 31/4436
A61K 31/416
C07D 49/02

US Classification:

514253010, 514342000, 514406000, 544360000, 546280400, 548365700

Abstract:

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein Ris —(CH)—X—(CH)-Aetc., wherein m and n are the same or different and each is 0 to 6, Xis a single bond, etc. and Ais a substituted Chydrocarbon ring group, etc.; Rand Rare the same or different and each is a hydrogen atom, —(CH)—X-(CH)-A, etc., wherein p and q are the same or different and each is 0 to 6, Xis a single bond, etc. and Ais an optionally substituted Chydrocarbon ring group, etc.; Ris —COR, etc., wherein Ris a hydrogen atom, etc.; and Rand Rare the same or different and each is a hydrogen atom, —(CH)—X—(CH)—R, etc., wherein m12 and m12 are the same or different and each is 0 to 6, Xis a single bond, etc. and Ris a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

US Patent:

20080242656, Oct 2, 2008

Filed:

Jun 19, 2007

Appl. No.:

11/765136

Inventors:

Andrew M. Fryer - Erie CO, US
Makoto Shiozaki - Osaka, JP
Nicole M. Littmann - Erie CO, US
Takashi Inaba - Osaka, JP
Steven W. Andrews - Longmont CO, US
Katsutaka Yasue - Osaka, JP
Ellen R. Laird - Longmont CO, US
Masahiro Yokota - Osaka, JP
Julia Haas - Boulder CO, US
Hiroto Imai - Osaka, JP
Katsuya Maeda - Osaka, JP
Yuichi Shinozaki - Osaka, JP
Yoshikazu Hori - Osaka, JP

International Classification:

A01N 43/00

US Classification:

51421109

Abstract:

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1)wherein Ris —W-A-W-A, W is —(CH)—X—(CH)—, wherein Wis —(CH)—X—(CH)—, m, m1, n and n1 are the same or different and each is 0 to 6, X and Xare the same or different and each is a single bond, etc., Ais an optionally substituted Chydrocarbon ring group, etc. and Ais a substituted Chydrocarbon ring group etc.; Ris —(CH)—CO—R, etc., wherein r is 0 to 6 and Ris a Calkoxy group, etc.; Rand Rare the same or different and each is a hydrogen atom, a Calkyl group, etc.; and Ris —COR, etc.; Rand Rare the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

US Patent:

20080306258, Dec 11, 2008

Filed:

May 6, 2008

Appl. No.:

12/149683

Inventors:

Takashi Inaba - Osaka, JP
Julia Haas - Boulder CO, US
Makoto Shiozaki - Osaka, JP
Nicole M. Littmann - Erie CO, US
Katsutaka Yasue - Osaka, JP
Steven W. Andrews - Longmont CO, US
Atushi Sakai - Osaka, JP
Andrew M. Fryer - Erie CO, US
Takafumi Matsuo - Osaka, JP
Ellen R. Laird - Longmont CO, US
Akira Suma - Osaka, JP
Yuichi Shinozaki - Osaka, JP
Yoshikazu Hori - Osaka, JP
Hiroto Imai - Osaka, JP
Tamotsu Negoro - Osaka, JP

International Classification:

C07D 243/08
C07D 413/14

US Classification:

540575, 544137

Abstract:

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1):wherein Ris —(CH)—X—(CH)-Aetc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and Ais a substituted Chydrocarbon ring group, etc.; Rand Rare the same or different and each is a hydrogen atom, —(CH)—X—(CH)-A, etc., wherein p and q are the same or different and each is 0 to 6, Xis a single bond, etc. and Ais an optionally substituted Chydrocarbon ring group, etc.; Ris —COR, etc., wherein Ris a hydrogen atom, etc.; and Rand Rare the same or different and each is a hydrogen atom, —(CH)—X—(CH)—Retc., wherein m12 and m12 are the same or different and each is 0 to 6, Xis a single bond, etc. and Ris a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

US Patent:

20090047246, Feb 19, 2009

Filed:

Feb 11, 2008

Appl. No.:

12/029399

Inventors:

Leonid Beigelman - San Mateo CA, US
Brad Buckman - Oakland CA, US
Vladimir Serebryany - Burlingame CA, US
Guangyi Wang - Carlsbad CA, US
Antitsa Dimitrova Stoycheva - Half Moon Bay CA, US
Steven W. Andrews - Longmont CO, US
Shawn Maurice Misialek - Redwood City CA, US
Andrew M. Fryer - Erie CO, US
Indrani Gunawardana - Longmont CO, US
Julia Haas - Boulder CO, US
Lily Huang - Longmont CO, US
Machender R. Madduru - Erie CO, US
Gan Zhang - Longmont CO, US
Karl Kossen - Brisbane CA, US
Scott D. Seiwert - Pacifica CA, US
Lawrence M. Blatt - San Francisco CA, US

Assignee:

InterMune, Inc. - Brisbane CA

International Classification:

A61K 38/21
C07D 409/06
A61K 31/405
A61K 31/506
C07D 403/08
A61K 31/404
C07D 209/20
A61K 31/675
C07F 9/572
A61K 31/437
C07D 471/02
C12N 9/99
A61K 31/44
A61K 39/395
A61K 31/427
C12N 9/50
C12N 9/00
C12Q 1/68
G01N 33/53

US Classification:

424 855, 548454, 514414, 514256, 544333, 548491, 514419, 514 80, 548414, 546113, 514300, 435184, 514350, 514365, 435219, 435183, 435 6, 435 71, 424 857

Abstract:

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.